HepTcell for Chronic Hepatitis B

Phase-Based Progress Estimates
Chronic Hepatitis BHepTcell - Biological
18 - 65
All Sexes
What conditions do you have?

Study Summary

This trial will test a new treatment for people with inactive chronic hepatitis B who have low levels of hepatitis B surface antigen. The treatment will be evaluated for its ability to fight the virus, its safety, and its ability to provoke an immune response.

Eligible Conditions
  • Chronic Hepatitis B

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: Baseline to Day 169

Baseline to Day 169
The proportion of patients achieving serologic clearance of Hepatitis B surface antigen (HBsAg)
The proportion of patients achieving serologic clearance of Hepatitis B virus (HBV) DNA
The proportion of patients achieving virologic responses

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

1 of 2
1 of 2

Experimental Treatment

Non-Treatment Group

80 Total Participants · 2 Treatment Groups

Primary Treatment: HepTcell · Has Placebo Group · Phase 2

Experimental Group · 1 Intervention: HepTcell · Intervention Types: Biological
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline to day 169

Who is running the clinical trial?

Altimmune, Inc.Lead Sponsor
15 Previous Clinical Trials
1,173 Total Patients Enrolled

Eligibility Criteria

Age 18 - 65 · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
How tall are you in inches?
How much do you weigh in pounds?

Who else is applying?

What state do they live in?
How old are they?
18 - 6566.7%
What site did they apply to?
Stanford University Department of Medicine66.7%
Toronto Liver Centre33.3%
What portion of applicants met pre-screening criteria?
Met criteria100.0%